Study of Venetoclax, a BCL2 Antagonist, for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Condition(s):Blastic Plasmacytoid Dendritic Cell NeoplasmLast Updated:February 8, 2023Active, not recruiting
Hide Studies Not Open or Pending
Condition(s):Blastic Plasmacytoid Dendritic Cell NeoplasmLast Updated:February 8, 2023Active, not recruiting
Condition(s):Blastic Plasmacytoid Dendritic Cell NeoplasmLast Updated:September 3, 2020Completed
Condition(s):Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)Last Updated:February 22, 2023Recruiting
Condition(s):Blastic Plasmacytoid Dendritic Cell NeoplasmLast Updated:April 15, 2022Active, not recruiting
Condition(s):Blastic Plasmacytoid Dendritic Cell NeoplasmLast Updated:September 23, 2022Recruiting
Condition(s):Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN); Acute Myeloid LeukemiaLast Updated:April 7, 2020Completed
Condition(s):Acute Myeloid Leukemia; Myelodysplastic Syndrome; Blastic Plasmacytoid Dendritic Cell NeoplasmLast Updated:June 14, 2022Recruiting
Condition(s):Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)Last Updated:July 14, 2022Recruiting
Condition(s):Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)Last Updated:July 31, 2019Terminated
Condition(s):Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)Last Updated:June 2, 2022Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.